Inhibitors of adrenal cortical function

  • Robert Gaunt
  • J. J. Chart
  • A. A. Renzi
Conference paper
Part of the Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie book series (ERGEBPHYSIOL, volume 56)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adlin, E. V., andB. J. Channick: Effects of prolonged inhibition of 11-beta-hydroxylase in the dog. Program, 46th Meeting, The Endocrine Society, 1964, p. 69, Abst. 93.Google Scholar
  2. Akinci, T., M. Apostolakis, andJ. Tamm: The effect of the 11β-hydroxylase blocking substance, SU-4885, on the urinary excretion of 17-hydroxy-corticosteroids and of melanocyte stimulating hormone-like activity. Acta endocr. (Kbh.)39, 253 (1962).Google Scholar
  3. Allen, M. J., andA. H. Corwin: Chemical studies on pinacols obtained fromp-aminoacetophenone andp-aminopropiophenone. J. Amer. chem. Soc.72, 117 (1950).Google Scholar
  4. ——, andW. W. Tullner: Progestational activity of 1,2-bis-(p-aminophenyl)-2-methylpropanone-1 dihydrochloride. Proc. Soc. exp. Biol. (N.Y.)74, 632 (1950).Google Scholar
  5. Andersson, E.: Indirekte måling af hypofysens ACTH-oproduktion hos normale og steroidbehandlede ved hjaelp af SU 4885, (Metopiron). Ugeskr. Laeg.123, 223 (1961).PubMedGoogle Scholar
  6. Andrade, J. R. de: Pituitary-adrenocortical reserve during corticosteroid therapy: A report on the methopyrapone test in ten patients taking long-continued small doses. J. clin. Endocr.24, 261 (1964).Google Scholar
  7. Aron, E., Y. Chambon etA. Voisin: Action d’un végetativolytique sur la réaction hypophysosurrénalienne du rat blanc. Application au dosage pratique des substances corticotropes. Bull. Acad. nat. Méd. (Paris)137, 417 (1953).Google Scholar
  8. Arth, G. E., H. Schwam, L. H. Sarett, andM. Glitzer: Aldosterone antagonists. 2′,3′α-Tetrahydrofuran-2′-spiro-17-(4-androsten-3-one) and related compounds. J. med. Chem.6, 617 (1963).PubMedGoogle Scholar
  9. Ashford, A., andM. Shapero: Effect of chlorpromazine, reserpine, benactyzine and phenobarbitone on the release of corticotrophin in the rat. Brit. J. Pharmacol.19, 458 (1962).PubMedGoogle Scholar
  10. Ball, J. N., andA. M. Slicher: Influence of hypophysectomy and of an adrenocortical inhibitor (SU-4885) on the stress-response of the white blood cells in the teleost fish,Mollienesia latipinnaLe Sueur. Nature (Lond.)196, 1331 (1962).Google Scholar
  11. Barlow, J. J., andD. A. Holub: Adrenal inhibitors and stimulators. Program, 43rd Meeting, The Endocrine Society, 1961, pp. 18–19, Abst. 34.Google Scholar
  12. Bartter, F. C.: The clinical use of aldosterone antagonists. Springfield, Ill.: Ch. C. Thomas 1960.Google Scholar
  13. Beigelman, P. M., M. A. Slusher, G. G. Slater, andS. Roberts: Effect of anesthetics and collection time on corticosteroid secretion by rat adrenal. Proc. Soc. exp. Biol. (N.Y.)93, 608 (1956).Google Scholar
  14. Bell jr.,J. T.: Histological and histochemical effects of DDD on goat adrenals, pituitaries, livers and kidneys. Anat. Rec.139, 207 (1961).Google Scholar
  15. Bencze, W. L., andM. J. Allen: Structure of amphenone B and related amphenones. J. org. Chem.22, 352 (1957).Google Scholar
  16. ——: Amphenone analogs. III. Pinacol-pinacolone type rearrangement in the pyridine series. J. Amer. chem. Soc.81, 4015 (1959a).Google Scholar
  17. ——: Chemistry and structure-activity relationships of amphenone analogues. J. med. pharm. Chem.1, 395 (1959b).PubMedGoogle Scholar
  18. —— andL. I. Barsky: Selective adrenal cortical and gonadal inhibitors. J. med. pharm. Chem.5, 1298 (1962).Google Scholar
  19. Bergenstal, D. M., R. Hertz, M. B. Lipsett, andR. H. Moy: Regression of adrenal cancer and suppression of adrenal function in man by o,p′ DDD. Trans. Ass. Amer. Phycns72, 341 (1959).Google Scholar
  20. Bergenstal, D. M., R. Hertz, M. B. Lipsett, andR. H. Moy: Chemotherapy of adrenocortical cancer with o,p′ DDD. Ann. intern. Med.53, 672 (1960a).Google Scholar
  21. ————: Regression of adrenal cancer and suppression of adrenal function in man by o,p′-DDD. Biological Activities of Steroids in Relation to Cancer, ed.G. Pincus andE. P. Vollmer, p. 463. New York: Academic Press 1960b.Google Scholar
  22. Bernard-Weil, E., C. Gros, P. Joly etM. David: Explorations hypothalamohypophyso-cortico-surrénaliennes (ACTH, CRF, SU-4′885) en pathologie neurologique et neurochirurgicale. Ann. Endocr. (Paris)24, 1061 (1963).Google Scholar
  23. Bertrand, J., C. Ollagnon, M. Forest, J. M. Saez, C. Cotte etB. Cautenet: Variations des 11 oxy et 11 désoxy-17 OHCS urinaires au cours du test au métopiron chez l’enfant. C. R. Soc. Biol. (Paris)157, 1617 (1963).Google Scholar
  24. Betz, D., andW. F. Ganong: Effect of chlorpromazine on pituitary-adrenal function in the dog. Acta endocr. (Kbh.)43, 264 (1963).Google Scholar
  25. Biglieri, E. G., andP. H. Forsham: Studies on the expanded extracellular fluid and the responses to various stimuli in primary aldosteronism. Amer. J. Med.30, 564 (1961).Google Scholar
  26. Birmingham, M. K., andE. Kurlents: Inactivation of ACTH by isolated rat adrenals and inhibition of corticoid formation by adrenocortical hormones. Endocrinology62, 47 (1958).PubMedGoogle Scholar
  27. Bissell, G. W., A. L. Scott, W. E. Farnsworth, andI. Winkler: A preliminary study of the use of 2-methyl-1,2-bis-(3-pyridyl)-1-propanone (SU 4885) as a test of pituitary function in man. N.Y. St. J. Med.59, 3596 (1959).Google Scholar
  28. Blatt, B.: Metopiron som led i kombinationsterapi ved resistente cirrotiske ødemer. Nord. Med.67, 15 (1962).PubMedGoogle Scholar
  29. Bledsoe, T., D. P. Island, R. L. Ney, andG. W. Liddle: The effects of o,p′DDD on the extra-adrenal metabolism of cortisol in man. Program, 45th Meeting, The Endocrine Society, 1963, p. 21, Abst. 41.Google Scholar
  30. ——, andG. W. Liddle: Modification of aldosterone secretion and electrolyte excretion in man by a chemical inhibitor of 18-oxidation. J. clin. Endocr.24, 740 (1964).PubMedGoogle Scholar
  31. Bleiberg, M. J.: Effect of technical perthane fractions on dog adrenal cortex. Endocrinology69, 13 (1961).Google Scholar
  32. —, andP. S. Larson: Studies on derivatives of 2,2-bis-(p-chlorophenyl)-1,1-dichloroethane (DDD, TDE) with special reference to their effects on the adrenal cortex. J. Pharmacol. exp. Ther.121, 421 (1957).PubMedGoogle Scholar
  33. Blohm, T. R., T. Kariya, andM. W. Laughlin: Effects of Mer-29, cholesterol synthesis inhibitor, on mammalian tissue lipids. Arch. Biochem.85, 250 (1959).PubMedGoogle Scholar
  34. Bohus, B., u.E. Endröczi: Untersuchungen über die Wirkung von Chlorpromazin auf das Hypophysen-Nebennierenrinden-System bei Ratten. Endokrinologie46, 126 (1964).PubMedGoogle Scholar
  35. Bonnycastle, D. D., andA. J. Bradley: Blocking action of Dilantin upon the pituitary-adrenal system. Fed. Proc.15, 403 (1956).Google Scholar
  36. ——: Diphenylhydantoin and the release of adrenocorticotropic hormone in the albino rat. Endocrinology66, 355 (1960).PubMedGoogle Scholar
  37. Bradlow, H. L., D. K. Fukushima, L. Hellman, andT. F. Gallagher: Transformation of epimeric Δ5-pregnene-3 β, 17, 20-tiols in man. J. clin. Endocr.24, 359 (1964).PubMedGoogle Scholar
  38. Bray, P. F., R. S. Ely, andV. C. Kelley: Studies of 17-hydroxycorticosteroids. VIII. Adrenocortical function in patients with convulsive disorder. Arch. Neurol. Psychiat. (Chic.)72, 583 (1954).Google Scholar
  39. Briot, C., J. Baillet etR. Tourneur: Etude d’une technique de blocage de la fonction corticosurrénalienne chez le rat. C.R. Soc. Biol. (Paris)157, 945 (1963).Google Scholar
  40. Brodish, A., andC. N. H. Long: ACTH-releasing hypothalamic neurohumor in peripheral blood. Endocrinology71, 298 (1962).Google Scholar
  41. Brown, E. A., andR. R. Burtner: Steroidal aldosterone blockers. VII. J. med. Chem.6, 732 (1963).PubMedGoogle Scholar
  42. Brown, J. H. U.: Influence of the drug DDD on adrenal cortical function in adult rats. Proc. Soc. exp. Biol. (N.Y.)83, 59 (1953).Google Scholar
  43. —, andR. B. Smith, III: Excretion of urinary 17-hydroxycorticoids in dogs fed DDD. Metabolism4, 542 (1955).PubMedGoogle Scholar
  44. Brown, J. H. U., J. R. K. Preedy, C. H. Brown, andB. L. Hallman: Action of an adrenocorticolytic drug in man. Lancet1959I, 1208.Google Scholar
  45. —, andJ. Jacobs: The influence of cortisone on the action of an adrenocorticolytic drug. Endocrinology61, 106 (1957).PubMedGoogle Scholar
  46. Brownie, A. C., andR. B. Hunter: The effect of adrenal cortical function in normal people of 1,2-bis-(β-pyridyl)-2-methyl-1-propanone-ditartrate (Su 4885). Scot. med. J.4, 103 (1959).Google Scholar
  47. —— andD. M. Shepherd: Biological effects of a compound related to amphenone. Proc. roy. Soc. Med.52, 819 (1959).PubMedGoogle Scholar
  48. Bugnon, C., etD. Lenys: Etude des effets du SC 9420 (Aldactone) et du SU 4885 (Métopyrone) sur l’appareil juxta-glomérulaire du rat blanc. C.R. Soc. Biol. (Paris)157, 1080 (1963).Google Scholar
  49. —, etJ. Racadot: Les types cellulaires du lobe anterieur de l’hypophyse chez le Porc. C.R. Soc. Biol. (Paris)157, 1931 (1963).Google Scholar
  50. Burdette, B. H., S. Leeman, andP. L. Munson: The reversal by nalorphine of the inhibitory effect of morphine on the secretion of adrenocorticotropic hormone in stress. J. Pharmacol. exp. Ther.132, 323 (1961).PubMedGoogle Scholar
  51. Burnham, D. F., A. L. Beyler, andG. O. Potts: Adrenal blocking action of a new steroid, cyanotrimethylandrostenolone. Fed. Proc.22, 270 (1963).Google Scholar
  52. Cazorla, A., andF. Moncloa: Action of 1,1-dichloro-2-p-chlorophenyl-2-o-chlorophenyl-ethane on dog adrenal cortex. Science136, 47 (1962).PubMedGoogle Scholar
  53. Cejka, V., L. A. de Vries, M. E. Smorenberg-Schoorl, J. J. van Daatselaar, J. G. G. Borst, andC. L. H. Majoor: Effect of heparinoid and spirolactone on the renal excretion of sodium and aldosterone. Lancet1960I, 317.Google Scholar
  54. Ceresa, F., A. Angeli eE. Strumia: Il flusso urinario dei 17-idrossicorticosteroidi durante inibizione metopironica nell’ipertiroidismo. Boll. Soc. ital. Biol. sper.39, 1247 (1963a).PubMedGoogle Scholar
  55. ———: Il flusso urinario dei 17-idrossicorticosteroidi durante inibizione metopironica nell’anoressia nervosa. Boll. Soc. ital. Biol. sper.39, 1244 (1963b).PubMedGoogle Scholar
  56. ———: Le débit urinaire stéroïdien au cours du freinage par la métopirone dans les hypercorticismes surrenaliens. Presse méd.71, 2466 (1963c).Google Scholar
  57. Chappel, C. I., D. Dvornik, P. Hill, M. Kraml, andR. Gaudry: Trans-1,4-bis-(2-chlorobenzylaminomethyl) cyclohexane dihydrochloride (AY 9944): A novel inhibitor of cholesterol biosynthesis. Circulation28, 651 (1963).Google Scholar
  58. Chart, J. J., andH. Sheppard: Pharmacology and biochemistry of some amphenone analogues and other adrenal cortical inhibitors. J. med. pharm. Chem.1, 407 (1959).PubMedGoogle Scholar
  59. ——: Hormonal steroids, pharmacology and therapeutics: Proc. First Internat. Congr. on Hormonal Steroids, vol. 1, p. 399. New York: Academic Press 1964.Google Scholar
  60. ——, andR. Gaunt: New amphenone analogs as adrenocortical inhibitors. Experientia (Basel)14, 151 (1958).Google Scholar
  61. ——, andN. Howie: Inhibitors of adrenal corticosteroid 17α-hydroxylation. Endocrinology71, 479 (1962).PubMedGoogle Scholar
  62. Chenault, S. B., J. H. McNeil, W. Starnes, M. Gautney, andS. R. Hill jr.: Studies of adrenal cortical suppression by amphenone in patients with secondary hyperaldosteronism. Amer. J. Med.25, 115 (1958).Google Scholar
  63. Christy, N. P., andA. D. Hofmann: Effects of diphenylhydantoin upon adrenal cortical function in man. Neurology (Minneap.)9, 245 (1959).Google Scholar
  64. —, andM. M. Knight: Inhibitory effect of chlorpromazine upon the adrenal cortical response to insulin hypoglycemia in man. J. clin. Invest.36, 543 (1957).PubMedGoogle Scholar
  65. Cleveland, W. W., M. Nikezic, andC. J. Migeon: Response to an 11β-hydroxylase inhibitor (SU-4885) in males with adrenal hyperplasia and in their parents. J. clin. Endocr.22, 281 (1962).PubMedGoogle Scholar
  66. Cobey, F. A., I. Taliaferro, andH. B. Haag: Effect of DDD and some of its derivatives on plasma 17-OH-corticosteroids in the dog. Science123, 140 (1956).PubMedGoogle Scholar
  67. ———: Further observations on effect on plasma 17-OH-corticosteroids in the dog of derivatives of 2,2-bis-(p-chlorophenyl)-1,1-dichloroethane (DDD, TDE). Proc. Soc. exp. Biol. (N.Y.)97, 491 (1958).Google Scholar
  68. Cole, D. F.: The action of an aldosterone antagonist on sodium transport across the ciliary epithelium. J. Endocr.24, vii (1962).Google Scholar
  69. Confalonieri, C., F. Porta eD. Zecca: II. Test del Metopirone applicato alla diagnostica funzionale delle amenorree. Ann. Ostet. Ginec.85, 77 (1963).PubMedGoogle Scholar
  70. Coppage jr., W. S., D. Island, M. Smith, andG. W. Liddle: Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11β-hydroxylation. J. clin. Invest.38, 2101 (1959).PubMedGoogle Scholar
  71. Cortés, J. M., andF. G. Péron: Lack of effect of chronic administration of p-aminobenzoic acid on the secretion of 18-hydroxydeoxycorticosterone and corticosterone by the rat adrenal. Steroids3, 551 (1964).Google Scholar
  72. Costa, P. J., andD. D. Bonnycastle: The adrenal cortical suppressant effect of two triazine analogs in the guinea pig. J. Pharmacol. exp. Ther.129, 214 (1960).PubMedGoogle Scholar
  73. —, andD. D. Bonnycastle: Effects of diphenylhydantoin (Dilantin) on adrenal cortical function. Arch. Neurol. Psychiat. (Chic.)74, 88 (1955).Google Scholar
  74. CoTui, F., W. Brinitzer, A. Orr, andE. Orr: Effect of chlorpromazine and of reserpine on adrenocortical function. Psychiat. Quart.34, 47 (1960).PubMedGoogle Scholar
  75. Crabbé, J., etJ. W. Meakin: La fonction corticosurrénale après traitement prolongé aux corticostéroïdes. Ann. Endocr. (Paris)22, 576 (1961).Google Scholar
  76. —, andP. de Weer: Action of aldosterone on the bladder and skin of the toad. Nature (Lond.)202, 298 (1964).Google Scholar
  77. Critchlow, V., H. S. Lipscomb, andR. Guillemin: Effect of CRF on maintenance of the adrenocorticotrophic function of anterior pituitary grafts. J. Endocr.25, 465 (1963).PubMedGoogle Scholar
  78. Cronheim, G., andN. Hyder: Effect of salicylic acid on adrenal-pituitary system. III. Studies on mechanism of this effect. Proc. Soc. exp. Biol. (N.Y.)86, 409 (1954).Google Scholar
  79. Cueto, C., andJ. H. U. Brown: The chemical fractionation of an adrenocorticolytic drug. Endocrinology62, 326 (1958a).PubMedGoogle Scholar
  80. ——: Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology62, 334 (1958b).PubMedGoogle Scholar
  81. Currie, A. R., J. E. Helfenstein, andS. Young: Massive adrenal necrosis in rats caused by 9,10-dimethyl-1,2-benzanthracene and its inhibition by metyrapone. Lancet1962II, 1199.Google Scholar
  82. Cushman jr.,P., C. Dickson, andJ. G. Hilton: Effects of a new inhibitor of cholesterol biosynthesis on adrenal cortical secretion in the dog. J. clin. Invest.43, 1270 (1964).Google Scholar
  83. —,C. D. Westermann, W. J. Athos, andJ. G. Hilton: Increased plasma ACTH-like activity following methopyrapone administration in the dog. Endocrinology73, 529 (1963).PubMedGoogle Scholar
  84. Daniels, H., W. J. van Amstel, W. Schopman, andC. van Dommelen: Effect of metopirone in a patient with adrenal cortical carcinoma. Acta endocr. (Kbh.)44, 346 (1963).Google Scholar
  85. Danowski, T. S., J. V. Bonesi, G. Sabeh, R. D. Sutton, M. W. Webster jr., andM. E. Sarver: Probabilities of pituitary-adrenal responsiveness after steroid therapy. Ann. intern. Med.61, 11 (1964).PubMedGoogle Scholar
  86. Dao, T. L., andY. Tanaka: Inhibitory effect of 3-methylcholanthrene on induction of massive necrosis of adrenal cortex by 7,12-dimethylbenz(a) anthracene. Proc. Soc. exp. Biol. (N.Y.)113, 78 (1963).Google Scholar
  87. Das Gupta, D., andC. J. P. Giroud: Effect of an aldosterone antagonist on the fluid retention of aminonucleoside nephrosis. Endocrinology65, 500 (1959).Google Scholar
  88. Davidson, E. T., W. S. Coppage jr., D. Island, andG. W. Liddle: Effects of steroid-17-spirolactones on aldosterone secretion, excretion, and metabolism in man. J. Lab. clin. Med.58, 505 (1961).PubMedGoogle Scholar
  89. Davidson, J. M., andS. Feldman: Adrenocorticotropin secretion inhibited by implantation of hydrocortisone in the hypothalamus. Science137, 125 (1962).PubMedGoogle Scholar
  90. ——: Cerebral involvement in the inhibition of ACTH secretion by hydrocortisone. Endocrinology72, 936 (1963).PubMedGoogle Scholar
  91. Davies, M. S., B. S. Hetzel, G. M. E. Kearney, andG. M. Wilson: The use of metyrapone as an aldosterone antagonist. Clin. Pharmacol. Ther.5, 296 (1964).PubMedGoogle Scholar
  92. Dill, R. E.: Adrenal cortical response in rats treated with diphenylhydantoin sodium. Anat. Rec.148, 366 (1964).Google Scholar
  93. Ditzel, J., P. F. Hansen, andN. Riskoer: Pituitary-adrenal function following hypophysectomy in man. Acta endocr. (Kbh.)45, 171 (1964).Google Scholar
  94. Dominguez, O. V., andL. T. Samuels: Mechanism of inhibition of adrenal steroid 11β-hydroxylase by methopyrapone (Metopirone). Endocrinology73, 304 (1963).PubMedGoogle Scholar
  95. Drill, V. A.: The aldosterone blocking effects of spirolactones. Jap. J. Pharmacol.11, 77 (1962).PubMedGoogle Scholar
  96. Dunihue, F. W., W. v. B. Robertson, andB. Machanic: Effect of the spironolactone, SC8109, on renal juxtaglomerular cell granulation in rats with a regenerating adrenal gland. Anat. Rec.142, 228 (1962).Google Scholar
  97. Dunlop, D.: Eighty-six cases of Addison’s disease. Brit. med. J.1963II, 887.Google Scholar
  98. Eberlein, W. R., andA. M. Bongiovanni: Plasma and urinary corticosteroids in the hypertensive form of congenital adrenal hyperplasia. J. biol. Chem.223, 85 (1956).PubMedGoogle Scholar
  99. Ebner, N.: Versuche mit Aldacton und Metopiron bei Akne vulgaris und endogenem Ekzem. Wien. med. Wschr.113, 253 (1963).Google Scholar
  100. Edgren, R. A., W. E. Hambourger, andD. W. Calhous: Production of adrenal atrophy by 6-methyl-17-acetoxy-progesterone, with remarks on the adrenal effects of other progestational agents. Endocrinology65, 505 (1959).PubMedGoogle Scholar
  101. Edmonds, C. J.: An aldosterone antagonist and diuretics in the treatment of chronic oedema and ascites. Lancet1960I, 509.Google Scholar
  102. Eechaute, W., E. Lacroix etR. Coessens: L’activité corticosurrénalienne sous l’influence de la réserpine et de l’iproniazide. Arch. int. Physiol.70, 117 (1962a).PubMedGoogle Scholar
  103. —— etJ. J. Bouckaert: L’activité du cortex surrénalien sous l’influence de la réserpine et de l’iproniazide. Arch. int. Pharmacodyn.139, 403 (1962b).Google Scholar
  104. Egdahl, R. H.: Cerebral cortical inhibition of pituitary-adrenal secretion. Endocrinology68, 574 (1961).PubMedGoogle Scholar
  105. —, andJ. B. Richards: Effect of chlorpromazine on pituitary ACTH secretion in the dog. Amer. J. Physiol.185, 235 (1956).PubMedGoogle Scholar
  106. ——, andD. M. Hume: Effect of reserpine on adrenocortical function in unanesthetized dogs. Science123, 418 (1956).PubMedGoogle Scholar
  107. Eisalo, A., andS. Talanti: On the effect of triparanol on the adrenal cortex of the rat: A histochemical study. J. Pharmacol. exp. Ther.137, 380 (1962).PubMedGoogle Scholar
  108. Eisenman, A. J., H. F. Fraser, andJ. W. Brooks: Urinary excretion and plasma levels of 17-hydroxycorticosteroids during a cycle of addiction to morphine. J. Pharmacol. exp. Ther.132, 226 (1961).PubMedGoogle Scholar
  109. Ertel, R. J., F. Ungar, andF. Halberg: Circadian rhythm in susceptibility of mice to toxic doses of Su-4885. Fed. Proc.22, 211 (1963).Google Scholar
  110. Farmer jr.,T. A., S. R. Hill jr.,J. A. Pittman jr., andJ. W. Herod: The plasma 17-hydroxycorticosteroid response to corticotropin, SU-4885 and lipopolysaccharide pyrogen. J. clin. Endocr.21, 433 (1961).PubMedGoogle Scholar
  111. Farrell, G., L. F. Fabre jr., andW. M. McIsaac: Effect of quinones on aldosterone secretion. Program, 46th Meeting, The Endocrine Society, 1964, p. 63, Abstr. 81.Google Scholar
  112. Fekete, G., andP. Görög: The inhibitory action of natural and synthetic glucocorticoids on adrenal steroidogenesis at the adrenal level. J. Endocr.27, 123 (1963).PubMedGoogle Scholar
  113. Feldschuh, J., I. I. Musacchio, andH. S. Kupperman: The effect of chlorpromazine upon the endogenous ACTH response to Metopirone (SU-4885). Program, 43rd Meeting, The Endocrine Society, 1961, p. 57, Abstr. 108.Google Scholar
  114. Ferrante, L., eA. Bertaggia: Utilità di un inibitore dell’attività 11β-idrossilasica del surrene (Metopirone) quale test per la diâgnosi differenziale in casi di neoplasia del cortico-surrene. Acta paediat. lat. (Parma)16, 41 (1963).Google Scholar
  115. Filippis, V. de: SU-4885 in oedema. Lancet1961II, 153.Google Scholar
  116. Fisher, D. A., T. C. Panos, andJ. C. Melby: Therapy of adrenocortical cancer with o,p′ DDD in two children. J. clin. Endocr.23, 218 (1963).Google Scholar
  117. Földes, J., O. Koref, T. Feher, andK. Steczek: Effect of Su 4885 on urinary oestrogens. J. Endocr.29, 207 (1964).Google Scholar
  118. Fortier, C.: Dual control of adrenocorticotropin release. Endocrinology49, 782 (1951).PubMedGoogle Scholar
  119. Fossey, B. M. de, H. Bricaire etL. de Gennes: Un nouveau test d’exploration hypophysaire: le test à la métopyrone ou Su 4885. Presse méd.38, 1635 (1961).Google Scholar
  120. Fotherby, K., A. D. Forrest, andS. G. Laverty: The effect of chlorpromazine on adrenocortical function. Acta endocr. (Kbh.)32, 425 (1959).Google Scholar
  121. Franken, F. H., K. Irmscher u.H. A. v. Schweinitz: Studien mit SU 4885 (Metopiron) bei Patienten mit therapierefraktärem Ascites und Oedemen. Klin. Wschr.40, 137 (1962).PubMedGoogle Scholar
  122. Fredrickson, D. S., R. E. Peterson, andD. Steinberg: Inhibition of adrenocortical steroid secretion by Δ4-cholestenone. Science127, 704 (1958).PubMedGoogle Scholar
  123. Fregly, M. J.: Effect of o,p′-DDD and SU-4885 on development of renal hypertension in rats. Physiologist6, 181 (1963).Google Scholar
  124. Frisch, E., andL. I. Gardner: Failure of suramin (Bayer 205; germanin) to cause changes in the adrenal cortex of the rat. Endocrinology63, 500 (1958).PubMedGoogle Scholar
  125. Froesch, E. R., A. Labhart, R. Neher, A. Prader u.W. Ziegler: Diagnostische Anwendung eines neuen Adrenostaticum. Schweiz. med. Wschr.89, 1232 (1959).Google Scholar
  126. Fujita, T., H. Ibayashi, K. Motohashi, T. Uchikawa, andS. Okinaka: Clinical applications of urinary ACTH assay. J. clin. Endocr.23, 143 (1963).PubMedGoogle Scholar
  127. Fukushima, D. K., T. F. Gallagher, W. Greenberg, andO. H. Pearson: Studies with an adrenal inhibitor in adrenal carcinoma. J. clin. Endocr.20, 1234 (1960).PubMedGoogle Scholar
  128. Gallagher, T. F.: Adrenocortical carcinoma in man. The effect of amphenone on individual ketosteroids. J. clin. Endocr.18, 937 (1958).PubMedGoogle Scholar
  129. —, andL. Hellman: The effect of ortho, para’ DDD on steroid hormone metabolites in adrenocortical carcinoma. Metabolism11, 1155 (1962).PubMedGoogle Scholar
  130. —, andD. Laszlo: Serial studies of steroid excretory patterns in metastatic adrenocortical carcinoma responsive to ACTH, cortisone and amphenone. J. clin. Endocr.16, 919 (1956).Google Scholar
  131. Ganong, W. F.: The central nervous system and the synthesis and release of adrenocorticotropic hormone. In: Advances in Neuroendocrinology, p. 92, ed.A. V. Nalbandov. Urbana, Illinois: Univ. Illinois Press 1963.Google Scholar
  132. —, andE. M. Gold: Changes in blood ACTH levels following administration of Su 4885 to adrenalectomized dogs. Physiologist3, 63 (1960).Google Scholar
  133. Ganong, W. F., B. L. Wise, andB. Zipf: The site of action of α-ethyltryptamine acetate (Monase) in blocking ACTH secretion. Program, 46th Meeting, The Endocrine Society, 1964, p. 42, Abstr. 39.Google Scholar
  134. Gans, I. H., andR. A. Ulstrom: Corticotropin production response to methopyrapone. Amer. J. Dis. Child.104, 258 (1962).PubMedGoogle Scholar
  135. Gantt, C. L.: Aldosterone antagonists. N. Y. St. J. Med.61, 756 (1961).Google Scholar
  136. Garmendia, F., W. E. Vaubel, u.E. F. Pfeiffer: Über das Verhalten der endogenen ACTH-Aktivität im menschlichen Plasma nach enzymatischer Blockade der Cortisol-Synthese mit Metopiron (SU 4885). I. Mitteilung. Untersuchungen an Stoffwechselgesunden. Klin. Wschr.41, 317 (1963).PubMedGoogle Scholar
  137. Garst, J. B., N. P. Shumway, H. Schwartz, andG. L. Farrell: Effect of aldactone on urinary aldosterone, sodium and potassium in essential hypertension. Fed. Proc.20, 180 (1961).Google Scholar
  138. Gaunt, R., J. J. Chart, andA. A. Renzi: Interactions of drugs with endocrines. In: Annual Review of Pharmacology Vol. 3, p. 109, ed. W. C. Cutting. Palo Alto, Cal.: Annual Reviews Inc. 1963.Google Scholar
  139. —,A. A. Renzi, N. Antonchak, G. J. Miller, andM. Gilman: Endocrine aspects of the pharmacology of reserpine. Ann. N.Y. Acad. Sci.59, 22 (1954).PubMedGoogle Scholar
  140. ——, andJ. J. Chart: Endocrine pharmacology of methyl reserpate derivatives Endocrinology71, 527 (1962).PubMedGoogle Scholar
  141. Geyer, G.: Erfolgreiche Behandlung eines Falles von Cushing-Syndrom mit o, p-DDD [2,2-bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroäthan]. Acta endocr. (Kbh.)40, 332 (1962).Google Scholar
  142. Gilder, H., C. McSherry, andJ. M. Beal: Effect of an aldosterone antagonist on gastric and renal function in dog. Fed. Proc.19, 166 (1960).Google Scholar
  143. Giles, C., andK. Griffiths: Inhibition of the aromatizing activity of human placenta by SU 4885. J. Endocr.28, 344 (1964).Google Scholar
  144. Girod, C. etJ.-C. Czyba: Influence de la dexaméthasone et de la métopirone sur la cytologie des îlots de Langerhans chez les SingeMacacus irusF. Cuv. C. R. Soc. Biol. (Paris)158, 78 (1964).Google Scholar
  145. Givner, M. L., M. Kraml, D. Dvornik, andR. Gaudry: An inhibitor of adrenal steroid 11 β-hydroxylase. Nature (Lond.)203, 317 (1964).Google Scholar
  146. Gláz, E., andK. Sugár: Effect of heparin and heparinoids on the synthesis of aldosterone and corticosterone by the rat adrenal gland. Endocrinology74, 159 (1964).PubMedGoogle Scholar
  147. Glenister, D. W., andF. E. Yates: Sex difference in the rate of disappearance of corticosterone-4-C14 from plasma of intact rats: further evidence for the influence of hepatic Δ4-steroid hydrogenase activity on adrenal cortical function. Endocrinology68, 747 (1961).PubMedGoogle Scholar
  148. Glenn, E. M., S. L. Richardson, andB. J. Bowman: Biologic activity of 6-alphamethyl compounds corresponding to progesterone, 17-alpha-hydroxyprogesterone acetate and compound S. Metabolism8, 265 (1959).PubMedGoogle Scholar
  149. Gold, E. M., R. Bigler, S. Newman, M. Angers, andV. C. di Raimondo: Studies of pituitary adrenocortical relationships with an 11-beta hydroxylase inhibitor of the adrenal cortex. Clin. Res.7, 64 (1959).Google Scholar
  150. —,V. C. di Raimondo, andP. H. Forsham: Quantitation of pituitary corticotropin reserve in man by use of an adrenocortical 11-beta hydroxylase inhibitor (SU-4885). Metabolism9, 3 (1960a).PubMedGoogle Scholar
  151. ——,J. R. Kent, andP. H. Forsham: Comparative effects of certain nonnarcotic central nervous system analgesics and muscle relaxants on the pituitary adrenocortical system. Ann. N.Y. Acad. Sci.86, 178 (1960b).PubMedGoogle Scholar
  152. Goodman, A. D.: Studies on the effect of omega-methyl-pantothenic acid in corticosterone secretion in the rat. Endicrinology66, 420 (1960).Google Scholar
  153. Gordon, S., S. Mauer, W. P. Cekleniak, andR. Partridge: Mechanism of triparanolinduced adrenal hypertrophy and reduced adrenal function. Endocrinology72, 643 (1963).PubMedGoogle Scholar
  154. Green, W. L., andS. H. Ingbar: Decreased corticotropin reserve as isolated pituitary defect. Arch. intern. Med.108, 945 (1961).PubMedGoogle Scholar
  155. Greenblatt, R. B., andW. E. Barfield: The progestational activity of 6-methyl-17-acetoxyprogesterone. Sth. med. J. (Bgham, Ala.)52, 345 (1959).Google Scholar
  156. Groot, J. de, andG. W. Harris: Hypothalamic control of the anterior pituitary gland and blood lymphocytes. J. Physiol. (Lond.)3, 335 (1950a).Google Scholar
  157. Groot, J. de, andG. W. Harris: Hypothalamic control of the secretion of adrenocorticotrophic hormone. J. Physiol. (Lond.)3, 12P (1950b).Google Scholar
  158. Guillemin, R., W. E. Dear, B. Nichols jr., andH. S. Lipscomb: ACTH releasing activityin vivo of a CRF preparation and lysine vasopressin. Proc. Soc. exp. Biol. (N.Y.)101, 107 (1959).Google Scholar
  159. —, andB. Rosenberg: Humoral hypothalamic control of anterior pituitary: A study with combined tissue cultures. Endocrinology57, 599 (1955).PubMedGoogle Scholar
  160. Gwinup, W. G., P. A. Lang, andJ. E. Johnson: Resistance of the chemical aberrations of primary hyperaldosteronism to alteration by 11-beta hydroxylase inhibition. Clin. Res.9, 27 (1961).Google Scholar
  161. Hair, W. W., andR. E. Bolinger: The effect of nitrogen mustard on adrenal function. Amer. J. med. Sci.241, 744 (1961).PubMedGoogle Scholar
  162. Halkerston, I. D. K., M. Feinstein, andO. Hechter: Increased responsivity of adrenals from reserpine-treated or stressed rats to steroidogenic activity of ACTH. Proc. Soc. exp. Biol. (N.Y.)115, 292 (1964).Google Scholar
  163. Hall, P. F.: Gonadotrophic stimulationin vitro andin vivo of testis from rabbits treated with triparanol. Endocrinology74, 201 (1964).PubMedGoogle Scholar
  164. —, andK. B. Eik-Nes: Human chorionic gonadotropin and testosterone formation. Fed. Proc.21, 197 (1962).Google Scholar
  165. ——, andL. T. Samuels: Influence of an inhibitor of 17 α-hydroxylation on the biosynthesis of testosterone by testicular tissue. Endocrinology73, 547 (1963).PubMedGoogle Scholar
  166. Hamburger, C.: Substitution of hypophysectomy by the administration of chlorpromazine in the assay of corticotrophin. Acta endocr. (Kbh.)20, 383 (1955).Google Scholar
  167. Hamwi, G. J., T. C. Skillman andJ. H. Mostow: Evaluation of SU-4885 in measuring pituitary reserve function. Clin. Res.9, 242 (1961).Google Scholar
  168. Harding, H. R., andG. O. Potts: The blocking effect of cyanotrimethylandrostanolone on the induction of liver tryptophan pyrrolase (TPO) activity by ACTH. Fed. Proc.23, 356 (1964).Google Scholar
  169. Harris, G. W., andC. Fortier: The regulation of anterior pituitary function, with special reference to the secretion of adrenocorticotrophic hormone. In: Fourth Annual Report on Stress, p. 106, ed.H. Selye andG. Heuser. Montreal: Acta, Inc. 1954.Google Scholar
  170. Harwood, C. T., andJ. W. Mason: Acute effects of tranquilizing drugs on the anterior pituitary-ACTH mechanism. Endocrinology60, 239 (1957).PubMedGoogle Scholar
  171. Heinen, G., H. Buchheit u.G. W. Oertel: Untersuchungen mit dem Adrenostatikum Su 4885 (Metopiron) in der Schwangerschaft. Klin. Wschr.41, 103 (1963).PubMedGoogle Scholar
  172. Helfenstein, J. E., andS. Young: Effect of 2-methyl-1,2-bis-(3-pyridy)-1-propanone (Metyrapone) on the production of mammary tumours induced in rats by oral feeding with dimethylbenzanthracene. Nature (Lond.)200, 1113 (1963).Google Scholar
  173. Heming, A. E., D. E. Holtkamp, J. F. Kerwin, L. F. Mansor, andJ. G. Dacanay: Effect of amphenone “B” on adrenal and thyroid function of adult ovariectomized rats. Proc. Soc. exp. Biol. (N.Y.)80, 154, (1952).Google Scholar
  174. Henke, W. J., R. P. Doe, andM. E. Jacobson: A test of pituitary reserve utilizing intravenous Su-4885, with a new method for extraction of 11-desoxycorticosteroids. J. clin. Endocr.20, 1527 (1960).PubMedGoogle Scholar
  175. Hertz, R., M. J. Allen, andW. W. Tullner: Effects of amphenone B on thyroid, adrenals and genital tract of the female rat. Proc. Soc. exp. Biol. (N.Y.)75, 627 (1950).Google Scholar
  176. —,J. A. Pittman, andM. M. Graff: Amphenone: Toxicity and effects on adrenal and thyroid function in man. J. clin. Endocr.16, 705 (1956).PubMedGoogle Scholar
  177. —, andW. W. Tullner: Endocrine effects of p,p′ diaminochalcone. Proc. Soc. exp. Biol. (N.Y.)115, 143 (1964).Google Scholar
  178. ——, andM. J. Allen: Selective inhibition of adrenal and thyroid stimulating effect of amphenone B by cortisone and thyroxine. Proc. Soc. exp. Biol. (N.Y.)77, 480 (1951).Google Scholar
  179. Hertz, R., M. J. Allen, J. A. Schricker, F. G. Dhyse, andL. F. Hallman: Studies on amphenone and related compounds. Recent Progr. Hormone Res.11, 119 (1955).Google Scholar
  180. Hierholzer, K.: Über die diuretische Wirkung des Adrenostatikums Methopyrapon. Dtsch. med. Wschr.89, 1167 (1964).PubMedGoogle Scholar
  181. Hoet, J. J., A. E. Renold, R. Hertz, andG. W. Thorn: Effects of amphenone in patients with disturbed carbohydrate metabolism. Diabetes6, 330 (1957).PubMedGoogle Scholar
  182. Hogness, J. R., N. D. Lee, andR. H. Williams: Effects of amphenone B on thyroid and adrenal functions. Endocrinology52, 378 (1953).PubMedGoogle Scholar
  183. —,R. H. Williams, andM. Lance: Effect of amphenone “B” on adrenal, thyroid and testes. Proc. Soc. exp. Biol. (N.Y.)79, 43 (1952).Google Scholar
  184. Hollander, W., A. V. Chobanian andR. W. Wilkins: The antihypertensive actions of mercurial, thiazide, and spirolactone diuretics. In: Diuresis and Diuretics, p. 297, ed.E. Buchborn andK. D. Bock, Berlin-Göttingen-Heidelberg: Springer 1959.Google Scholar
  185. Holloszy, J., andA. B. Eisenstein: Effect of triparanol (MER/29) on corticosterone secretion by rat adrenals. Proc. Soc. exp. Biol. (N.Y.)107, 347 (1961).Google Scholar
  186. Holub, D. A., andJ. W. Jailer Sodium and water diuresis in cirrhotic patients with intractable ascites following chemical inhibition of aldosterone synthesis. Ann. intern. Med.53, 425 (1960).PubMedGoogle Scholar
  187. ——,J. I. Kitay, andA. G. Frantz: Direct and indirect estimation of pituitary adrenocorticotropin reserves in man following adrenal steroid therapy. J. clin. Endocr.19, 1540 (1959).PubMedGoogle Scholar
  188. —,F. H. Katz, andJ. W. Jailer: Inhibition by 6-methyl-17-acetoxyprogesterone of ACTH synthesis and release in the rat. Endocrinology68, 173 (1961).PubMedGoogle Scholar
  189. Holzbauer, M., andM. Vogt: The action of chlorpromazine on diencephalic sympathetic activity and on the release of adrenocorticotrophic hormone. Brit. J. Pharmacol.9, 402 (1954).PubMedGoogle Scholar
  190. ——: The release of corticotrophin during severe stress in the rat treated with pentobarbitone and morphine. Acta endocr. (Kbh.)29, 231 (1958).Google Scholar
  191. Hornbein, T. F.: Adrenal cortical response to chronic hypoxia. J. appl. Physiol.17, 246 (1962).PubMedGoogle Scholar
  192. Huggins, C., andS. Morii: Selective adrenal necrosis and apoplexy induced by 7,12-dimethylbenz(a)anthracene. J. exp. Med.114, 761 (1961).Google Scholar
  193. Hume, D. M., andD. H. Nelson: Adrenal cortical function in surgical shock. Surg. Forum5, 568 (1955).PubMedGoogle Scholar
  194. Humphreys, E. M., andL. Donaldson: Degeneration of the adrenal cortex produced by germanin. Amer. J. Path.17, 767 (1941).PubMedGoogle Scholar
  195. Ichii, S., E. Forchielli, C. E. Cassidy, C. B. Rosoff, andR. I. Dorfman: Biosynthesis of androgens by homogenates of normal and abnormal human adrenal glands. Biochem. biophys. Res. Commun.9, 344 (1962).PubMedGoogle Scholar
  196. Ingle, D. J.: A comparison of the resistance of male and female rats to cortin. Endocrinology24, 194 (1939).Google Scholar
  197. —: The functional interrelationship of the anterior pituitary and the adrenal cortex. Ann. intern. Med.35, 652 (1951).PubMedGoogle Scholar
  198. Jailer, J. W., andD. A. Holub: Congenital adrenal hyperplasia. Clin. Endocr.1, 354 (1960).Google Scholar
  199. Jasmin, G., andG. L. Richer: Effect of nialamide on plasma and adrenal corticosterone in rats. Program, 43rd Meeting, The Endocrine Society, 1961, p. 70, Abstr. 133.Google Scholar
  200. Jenkins, J. S.: An inhibitor of adrenal steroid 11-hydroxylation. Proc. roy. Soc. Med.52, 260 (1959).PubMedGoogle Scholar
  201. —,J. W. Meakin andD. H. Nelson: A comparison of the inhibitory effects of 2-methyl-1,2-bis-(3-pyridyl)-1-propanone and amphenone B on adrenal cortical secretion in the dog. Endocrinology64, 572 (1959).PubMedGoogle Scholar
  202. ———, andG. W. Thorn: Inhibition of adrenal steroid 11-oxygenation in the dog. Science128, 478 (1958).PubMedGoogle Scholar
  203. Jenkins, J. S., L. Potheir, W. J. Reddy, D. H. Nelson, andG. W. Thorn: Clinical experience with selective inhibition of adrenal function. Brit. med. J.1959I, 398.Google Scholar
  204. Lebacq, E., A. Tirzmalis, J. Gossart etP. Duez: Effet diurétique du Su-4885, inhibiteur de la 11β-hydroxylation dans le cortex surrénal. Rev. franç. Etud. clin. biol.6, 916 (1961).PubMedGoogle Scholar
  205. Leeman, S. E., D. W. Glenister, andF. E. Yates: Characterization of a calf hypothalamic extract with adrenocorticotropin-releasing properties: evidence for a central nervous system site for corticosteroid inhibition of adrenocorticotropin release. Endocrinology70, 249 (1962).PubMedGoogle Scholar
  206. Lefer, A. M., andG. R. Nadzam: Cardiovascular effects of Su-4885 (Mepyrapone), an inhibitor of corticosteroid biosynthesis. Proc. Soc. exp. Biol. (N.Y.)115 356 (1964).Google Scholar
  207. —, andD. C. Sutfin: Cardiovascular effects of catecholamines in experimental adrenal insufficiency. Amer. J. Physiol.206, 1151 (1964).PubMedGoogle Scholar
  208. LeSher, D. A., andF. E. Shideman: The influence of 2-amino-4-(p-chloroanalino)-s-triazine on the renal excretion of water, potassium and sodium in the rat and dog. J. Pharmacol. exp. Ther.116, 38 (1956).Google Scholar
  209. Levy, J. V., andV. Richards: Effects of a potent aldosterone antagonist on contractile and electrical properties of isolated rabbit atria. Clin. Res.10, 73 (1962).Google Scholar
  210. Liddle, G. W.: Sodium diuresis induced by steroidal antagonists of aldosterone. Science126, 1016 (1957).PubMedGoogle Scholar
  211. —: Tests of adrenocortical reserve, pituitary reserve, and pituitary-adrenal suppressibility. Clin. Endocr.1, 672 (1960).Google Scholar
  212. —: Specific and non-specific inhibition of mineralocorticoid activity. Metabolism10, 1021 (1961).Google Scholar
  213. —,H. L. Estep J. W. Kendall jr.,W. C. Williams jr. andA. W. Townes: Clinical application of a new test of pituitary reserve. J. clin. Endocr.19, 875 (1959).PubMedGoogle Scholar
  214. —,D. Island, H. Estep, andG. M. Tomkins: Modification of adrenal steroid patterns in man by means of an inhibitor of 11-beta-hydroxylase. J. clin. Invest.37, 912 (1958a).Google Scholar
  215. ——,E. M. Lance, andA. P. Harris: Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11β-hydroxylation. J. clin. Endocr.18, 906 (1958b).PubMedGoogle Scholar
  216. Liguori, G., G. F. Guiso, andL. Campanacci: The effects of Metopirone on glucose metabolism. Metabolism13, 499 (1964).PubMedGoogle Scholar
  217. Lohrenz, F. N., R. Fernandez, andR. P. Doe: Isolated thyrotropin deficiency. Review and report of three cases. Ann. intern. Med.60, 990 (1964).Google Scholar
  218. Louros, N., M. Batrinos, D. Kaskarelis, M. Pavlayou, andB. Terzis: Pituitary corticotrophin reserve in gonadal dysgenesis. Lancet1963II, 805.Google Scholar
  219. Lynn jr.,W. S., andR. H. Brown: Effects of amphenone B on the enzymatic properties of testicular microsomes. J. biol. Chem.232, 1005 (1958).PubMedGoogle Scholar
  220. Maanen, E. F. van, T. R. Blohm, W. L. Kuhn, J. G. Greslin, J. K. Smith, L. J. Lerner andD. Holtkamp: Cardiovascular, adrenal, and general biological effects of MER-29, a cholesterol synthesis inhibitor. Fed. Proc.18, 454 (1959).Google Scholar
  221. Mach, R. S., etA. F. Muller: L’inhibition de la sécrétion de l’aldostérone par l’amphénone. Schweiz. med. Wschr.87, Beiheft 14 406 (1957).PubMedGoogle Scholar
  222. Mäkelä, S., E. Näätänen, andU. K. Rinne: The response of the adrenal cortex to psychic stress after meprobamate treatment. Acta endocr. (Kbh.)32, 1 (1959).Google Scholar
  223. Mahfouz, M., andE. A. Ezz: The effect of reserpine and chlorpromazine on the response of the rat to acute stress. J. Pharmacol. exp. Ther.123, 39 (1958).PubMedGoogle Scholar
  224. Maickel, R. P., E. O. Westermann, andB. B. Brodie: Effects of reserpine and coldexposure on pituitary-adrenocortical function in rats. J. Pharmacol. exp. Ther.134, 167 (1961).PubMedGoogle Scholar
  225. Majoor, C. L. H., A. P. Jansen, R. J. A. F. M. Schlatmann, J. van der Korst, andH. Prenen: Heparin and related sulphated polysaccharides as diuretic and aldosterone suppressing drugs in man and dog. Acta cardiol. (Brux.)14, 657 (1962a).Google Scholar
  226. ———,H. Frohn, andH. Prenen: Investigations on the influence of heparin and some heparinoids upon the renal excretion of sodium and adrenal steroids — especially aldosterone — in man and dog. Folia med. neerl., Add.1, 79 (1962b).Google Scholar
  227. Majoor, C. L. H., A. P. Jansen, R. J. A. F. M. Schlatmann, andH. Prenen: Excretion pattern and mechanism of diuresis induced by heparin. Clin. chim. Acta5, 591 (1960).PubMedGoogle Scholar
  228. Mann, N. M.: Gynecomastia during therapy with spironolactone. J. Amer. med. Ass.184, 778 (1963).Google Scholar
  229. Marks, B. H., M. Alpert, andF. A. Kruger: Effect of amphenone upon steroidogenesis in the adrenal cortex of the golden hamster. Endocrinology63, 75 (1958).PubMedGoogle Scholar
  230. —, andJ. Vernikos-Danellis: Effect of acute stress on the pituitary gland: ethionine on stress-induced ACTH release. Endocrinology72, 582 (1963).Google Scholar
  231. Marks, L. J., G. Benjamin, F. J. Duncan, andJ. V. I. O’Sullivan: Comparative effects of ethinyl estradiol, 17α-ethyl-19-nortestosterone and methyltestosterone on the plasma clearance of infused cortisol. J. clin. Endocr.21, 826 (1961).PubMedGoogle Scholar
  232. —,J. C. Doiron, andH. T. Oyama: Effect of triparanol on adrenocortical function of man. New Engl. J. Med.266, 965 (1962).PubMedGoogle Scholar
  233. Martin, M. M., andD. E. Hellman: Temporal variation in Su-4885 responsiveness in man: Evidence in support of circadian variation in ACTH secretion. J. clin. Endocr.24, 253 (1964).PubMedGoogle Scholar
  234. Marton, A. V., E. Greselin, M. Givner, andK. Voith: Effect of a novel hypocholesterolemic agent,trans-1,4-bis-(2-chloro-benzylaminomethyl)-cyclohexane dihydrochloride (AY-9944) on adrenal morphology. Endocrinology75, 469 (1964).PubMedGoogle Scholar
  235. Mason, J. W., andJ. V. Brady: Plasma 17-hydroxycorticosteroid changes related to reserpine effects on emotional behavior. Science124, 983 (1956).PubMedGoogle Scholar
  236. Matsuda, K., C. Duyck, J. W. Kendall jr., andM. A. Greer: Pathways by which traumatic stress and ether induce increased ACTH release in the rat. Endocrinology74, 981 (1964).PubMedGoogle Scholar
  237. McCann, S. M.: Effect of hypothalamic lesions on the adrenal cortical response to stress in the rat. Amer. J. Physiol.175, 13 (1953).PubMedGoogle Scholar
  238. —,A. Fruit, andB. D. Fulford: Studies on the loci of action of cortical hormones in inhibiting the release of adrenocorticotrophin. Endocrinology63, 29 (1958).PubMedGoogle Scholar
  239. McCarthy, J. L., R. C. Corley, andM. X. Zarrow: Effect of goitrogens on adrenal gland of the rat. Amer. J. Physiol.197, 693 (1959).Google Scholar
  240. —, andR. L. Murphree: Adrenal atrophy and thyroid inhibition following PABA. Proc. Soc. exp. Biol. (N.Y.)105, 515 (1960).Google Scholar
  241. McCullagh, E. P., andH. A. Tretbar: Treatment of Cushing’s syndrome with amphenone: report of two cases, one with probable thymoma. j. clin. Endocr.18, 134 (1958).PubMedGoogle Scholar
  242. McDonald, R. K., F. T. Evans, V. K. Weise, andR. W. Patrick: Effect of morphine and nalorphine on plasma hydrocortisone levels in man. J. Pharmacol. exp. Ther.125, 241 (1959).PubMedGoogle Scholar
  243. McIntosh, J. W., N. Anderson, H. L. Duthie, andA. P. M. Forrest: The effect of an adrenal inhibitor (SU 4885) on gastric secretion in dogs. Gut1, 345 (1960).PubMedGoogle Scholar
  244. Meakin, J. W., M. S. Tantongco, J. Crabbé, T. B. Bayles, andD. H. Nelson: Pituitary-adrenal function following long-term steroid therapy. Amer. J. Med.29, 459 (1960).Google Scholar
  245. Meites, J., C. S. Nicoll andP. K. Talwalker: The central nervous system and the secretion and release of prolactin. In: Advances in Neuroendocrinology, p. 238, ed. A. V. Nalbandov. Urbana, Illinois: Univ. Illinois Press 1963.Google Scholar
  246. Melby, J. C.: Current status of tests of adrenocortical function, Part 2. Postgrad. Med.30, A-18 (1961).Google Scholar
  247. Melby, J. C., S. L. Dale, andM. St. Cyr: Reduction of adrenal steroid production by an inhibitor of cholesterol biosynthesis (MER-29). Program, 43rd Meeting, The Endocrine Society, 1961 a, p. 19, Abstr. 35.Google Scholar
  248. ———: Reduction of adrenal-steroid production by an inhibitor of cholesterol biosynthesis. New Engl. J. Med.264, 583 (1961b).PubMedGoogle Scholar
  249. —,T. E. Wilson, andS. L. Dale: Blood cholesterol and steroid hormone production. J. clin. Invest.43, 1282 (1964).Google Scholar
  250. Mestman, J. H., andD. H. Nelson: Inhibition by estrogen administration of adrenalpituitary response to methopyrapone. J. clin. Invest.42, 1529 (1963).PubMedGoogle Scholar
  251. Mills, J. N., S. Thomas, andK. S. Williamson: Does spironolactone block the renal effects of cortisol. J. Physiol. (Lond.)155, 18P (1961).Google Scholar
  252. ———: The blocking by spirolactones of the actions of aldosterone and cortisol upon the human kidney. J. Endocr.23, 357 (1962).PubMedGoogle Scholar
  253. Mokler, C. M.: Antiarrhythmic activity of various steroidal spirolactones in dogs. Proc. Soc. exp. Biol. (N.Y.)105, 257 (1960).Google Scholar
  254. Molnar, G. D., V. R. Mattox, andR. C. Bahn: Clinical and therapeutic observations in adrenal cancer: A report on 7 patients treated with o,p′-DDD. Cancer (Philad.)16, 259 (1963).Google Scholar
  255. Moncloa, F., andE. Pretell: Cortisol secretion rate, ACTH and methopyrapone tests in high altitude native residents. J. clin. Endocr.24, 915 (1964).PubMedGoogle Scholar
  256. Monsaingeon, A., J. L. Camus etA. Ennuyer: Tumeur cortico-surrénalienne féminisante chez une femme ménopausée. Comparaison des effects endocriniens de l’action chirurgicale et du traitement par l’OP’DDD. Presse méd.71, 2087 (1963).PubMedGoogle Scholar
  257. Montanari, R., andM. A. Stockham: Effects of single and repeated doses of reserpine on the secretion of adrenocorticotrophic hormone. Brit. J. Pharmacol.18, 337 (1962).PubMedGoogle Scholar
  258. Moor, P. de, O. Steeno, andR. Deckx: Factors affecting the binding of cortisol by transcortin. Acta endocr. (Kbh.)44, 107 (1963).Google Scholar
  259. Morii, S., andC. Huggins: Adrenal apoplexy induced by 7,12-dimethylbenz(a)anthracene related to corticosterone content of adrenal gland. Endocrinology71, 972 (1962).Google Scholar
  260. Mosonyi, L., L. Pollak, R. Zulik, andGy. Karolyhazi: Streptomycin and endocrine system. Experientia (Basel)12, 311 (1956).Google Scholar
  261. Moy, R. H.: Studies of the pharmacology of o,p′ DDD in man. J. Lab. clin. Med.58, 296 (1961).PubMedGoogle Scholar
  262. Muldowney, F. P., andP. Banks: Kaluretic effect of heparin. Lancet1960I, 548.Google Scholar
  263. Munson, P. L.: Endocrine pharmacology: Selected topics. In: Annual Review of Pharmacology, vol. 1, p. 315, ed.W. C. Cutting, R. H. Dreisbach, H. W. Elliott. Palo Alto, Cal.: Annual Reviews, Inc. 1961.Google Scholar
  264. —: Pharmacology of neuroendocrine blocking agents. In: Advances in Neuroendocrinology, p. 427, ed.A. V. Nalbandov. Urbana, Illinois: Univ. Illinois Press 1963.Google Scholar
  265. —, andF. N. Briggs: The mechanism of stimulation of ACTH secretion. Recent Progr. Hormone Res.11, 83 (1955).Google Scholar
  266. Nagra, C. L., J. G. Birnie, andR. K. Meyer: Suppression of the output of corticosterone in the pheasant by methopyrapone (Metopirone). Endocrinology73, 835 (1963).PubMedGoogle Scholar
  267. Nasmyth, P. A.: The effect of chlorpromazine on adrenocortical activity in stress. Brit. J. Pharmacol.10, 336 (1955).PubMedGoogle Scholar
  268. Neher, R., andF. W. Kahnt: Modifiers of adrenocortical function. Proc. 2nd Internat. Pharmacological Meeting. Vol. 4 Drugs and Enzymes (in press).Google Scholar
  269. Nelson, A. A., andG. Woodard: Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis-(parachlorophenyl)-1,1-dichloroethane (DDD or TDE). Arch. Path.48, 387 (1949).PubMedGoogle Scholar
  270. Nelson, D. H., R. H. Egdahl, andD. M. Hume: Corticosteroid secretion in the adrenal vein of the non-stressed dog exposed to cold. Endocrinology58, 309 (1956).PubMedGoogle Scholar
  271. Netto, A. da S. C., B. L. Wajchenberg, C. Ravaglia, V. G. Perreira, J. Shnaider, A. A. Pupo, andA. B. de U. Cintra: Treatment of adrenocortical cancer with o,p′-DDD. Ann. intern. Med.59, 74 (1963).PubMedGoogle Scholar
  272. Ney, R. L., W. S. Coppage jr., N. Shimizu, D. P. Island, C. F. Zukoski, andG. W. Liddle: Effects of triparanol on the secretion and metabolism of adrenal corticosteroids. J. clin. Endocr.22, 1057 (1962).PubMedGoogle Scholar
  273. Nichols, J., C. Davis, andH. D. Green: Effect of hypophysectomy, DDD treatment, and surgical trauma on the oxygen consumption of the various zones of the adrenal cortex. Endocrinology53, 541 (1953).PubMedGoogle Scholar
  274. Nichols, J., andL. I. Gardner: Production of insulin sensitivity with the adrenocorticolytic drug DDD (2,2-bis-(parachlorophenyl)-1,1-dichloroethane. J. Lab. clin. Med.37, 229 (1951).PubMedGoogle Scholar
  275. —, andH. D. Green: Effect of DDD treatment on metabolic response of dogs to ACTH injection. Amer. J. Physiol.176, 374 (1954).PubMedGoogle Scholar
  276. —, andG. Hennigar: Studies on the adrenal during simulataneous administration of DDD and amphenone. Endocrinology61, 226 (1957a).PubMedGoogle Scholar
  277. ——: Studies on DDD, 2,2-bis-(parachlorophenyl)-1,1-dichloroethane. Exp. Med. Surg.15, 310 (1957b).PubMedGoogle Scholar
  278. W. F. Prestley, andF. Nichols: Effects of m,p′-DDD in a case of adrenal cortical carcinoma (a preliminary report). Curr. ther. Res.3, 266 (1961).PubMedGoogle Scholar
  279. —, andA. W. Richardson: Effects of DDD on steroid response and blood flow through the adrenal after ACTH. Proc. Soc. exp. Biol. (N.Y.)104, 539 (1960).Google Scholar
  280. —, andH. L. Sheehan: Effect of partial adrenal cortical atrophy on the course of alloxan diabetes. Endocrinology51, 362 (1952).PubMedGoogle Scholar
  281. Ohler, E. A., andR. W. Sevy: Inhibition of stress induced adrenal ascorbic acid depletion by morphine, dibenzyline and adrenal cortical extract. Endocrinology59, 347 (1956).PubMedGoogle Scholar
  282. Oliveira Coutinho, J. S. de, A. Ubatuba, C. Alberto Leite yF. Ubatuba: Avaliacao da reserva hipofisária nos estados de desnutricao cronica por meio do SU 4885. Relato preliminar. Arch. bras. Endocr.11, 135 (1962).Google Scholar
  283. Oliver, J. T., andR. C. Troop: Plasma corticosterone levels in stressed rats following the administration of pentobarbital, morphine and diphenylhydantoin. Steroids1, 670 (1963).Google Scholar
  284. Olivereau, M.: Metopirone et interrénal chez l’anguille (Anguilla anguilla L.). C.R. Soc. Biol. (Paris)157, 1207 (1963).Google Scholar
  285. Olling, Ch. C. J., andD. de Wied: Inhibition of the release of corticotrophin from the hypophysis by chlorpromazine. Acta endocr. (Kbh.)22, 283 (1956).Google Scholar
  286. Oppenheimer, J. H., L. V. Fisher, andJ. W. Jailer: Disturbance of the pituitaryadrenal interrelationship in diseases of the central nervous system. J. clin. Endocr.21, 1023 (1961).PubMedGoogle Scholar
  287. Oriol-Bosch, A., andK. B. Eik-Nes: Effect of a hepatocatalase preparation (Caperase) on adrenal function in the guinea pig. Metabolism13, 319 (1964).PubMedGoogle Scholar
  288. Paris, J.: On the diagnosis of Addison’s disease and Cushing’s syndrome by laboratory methods. Proc. Mayo Clin.39, 26 (1964).PubMedGoogle Scholar
  289. Paroli, E., andP. Melchiorri: Urinary excretion of hydroxysteroids, 17-ketosteroids and aldosterone in rats during a cycle of treatment with morphine. Biochem. Pharmacol.6, 1 (1961a).PubMedGoogle Scholar
  290. —: Inhibitory effect of morphine on metabolism of adrenal and testicular steroids. Biochem. Pharmacol.6, 18 (1961b).PubMedGoogle Scholar
  291. Pasqualini, J. R.: Identification of 3α, 17α, 21-trihydroxy-5α-pregnane (allotetrahydro-17α-hydroxy-cortexone) and 3α,21-dihydroxy-5α-pregnane (allo-tetrahydro-cortexone in human urine. Experientia (Basel)19, 657 (1963).Google Scholar
  292. Peenen, P. F. van, andE. L. Way: Effect of certain central nervous system depressants on pituitary-adrenal activating agents. J. Pharmacol. exp. Ther.120, 261 (1957).Google Scholar
  293. Pekkarinen, A., U. Rinne, H. Saarimaa, andC. Sourander: The determination of the pituitary corticotrophin reserve by a two-day metyrapone (Metopirone®) test in psychiatric patients. Acta physiol. scand.59, Suppl. 213, 122 (1963).Google Scholar
  294. Peng, C. H. L., andE. O’F. Walsh: Effects of morphine on the hormonal control of metabolism. I.In vitro effects of morphine and hydrocortisone on utilization of glucose by muscle of normal and chronically morphinised rats. Biochem. Pharmacol.12, 921 (1963).PubMedGoogle Scholar
  295. Perrini, M., N. Piliego eL. Pinto: Gli inibitori dell’aldosterone nella terapia diuretica effetti del Metopirone e del progesterone sulla eliminazione dell’adosterone e degli elettroliti. Folia endocr. (Pisa)15, 42 (1962).Google Scholar
  296. Peterson, R. E., R. Hertz, andH. A. Lubs: Suppression of biosynthesis of adrenal steroids in man by amphenone. Proc. Soc. exp. Biol. (N.Y.)94, 421 (1957).Google Scholar
  297. Plager, J. E., G. A. Bray, andJ. E. Jackson: Pituitary-ACTH response to Metopirone and endotoxin administration in the dog. Encocrinology72, 876 (1963).Google Scholar
  298. Porter, G. A., andI. S. Edelman: The action of aldosterone and related corticosteroids on sodium transport across the toad bladder. J. clin. Invest.43, 611 (1964).PubMedGoogle Scholar
  299. Porter, J. C., andH. W. Rumsfeld jr.: Effect of lyophilized plasma and plasma fractions from hypophyseal-portal vessel blood on adrenal ascorbic acid. Endocrinology58, 359 (1956).PubMedGoogle Scholar
  300. Porter, R. W.: The central nervous system and stress-induced eosinopenia. Recent Progr. Hormone Res.10, 1 (1954).Google Scholar
  301. Possanza, G. J., J. T. Oliver, N. J. Sawyer andR. C. Troop: Effects of 6-methyl-17-acetoxy-progesterone on pituitary-adrenal function. Biochem. Pharmacol.13, 361 (1964).PubMedGoogle Scholar
  302. Potts, G. O., D. F. Burnham, andA. L. Beyler: Inhibitory action of two new steroids on the adrenal cortex of rats. Fed. Proc.22, 166 (1963).Google Scholar
  303. Rapp, J. P.: Effect of an aldosterone antagonist on electrolytes and juxtaglomerular granularity in adrenal regeneration hypertension. Endocrinology75, 326 (1964).PubMedGoogle Scholar
  304. Reed, P. I., C. B. Clayman, andW. L. Palmer: Adrenocortical and pituitary responsiveness following long-term, high dosage corticotropin administration. Ann. intern. Med.61, 1 (1964).PubMedGoogle Scholar
  305. Reichelt, A., D. Voth, H. Müller-Marienburg, u.M. Kohlhardt: Zum Einfluss von Angiotensin II auf die Nebennierenrinde unter chemischer Adrenostase mit SU 4885 (Metopiron). Experientia (Basel)20, 451 (1964).Google Scholar
  306. Renold, A. E., J. Crabbé, L. Hernando-Avendano, D. H. Nelson, E. J. Ross, K. Emerson jr., andG. W. Thorn: Inhibition of aldosterone secretion by amphenone in man. New Engl. J. Med.256, 16 (1957).PubMedGoogle Scholar
  307. Renzi, A. A., M. Gilman, andR. Gaunt: ACTH-suppressing action of aldosterone. Proc. Soc. exp. Biol. (N.Y.)87, 144 (1954).Google Scholar
  308. Rerup, C., andP. Hedner: The effect of pentobarbital (Nembutal, Mebumal NFN) on corticotrophin release in the rat. Acta endocr. (Kbh.)39, 518 (1962).Google Scholar
  309. Řežábek, K., andZ. Votava: The action of some antihistaminics and neuroplegics on the release of ACTH in surgical stress in rats. Arch. int. Pharmacodyn.108, 279 (1956).PubMedGoogle Scholar
  310. Richmond, L., J. Chappell, andW. W. Cleveland: Response of children to methopyrapone (Metopirone). J. Pediat.64, 381 (1964).PubMedGoogle Scholar
  311. Roche, J., R. Michel, P. Jouan etM. Cormer: Action inhibitrice de la 2-méthyl-1,2-bis-(3-pyridyl)-1-propanone (SU 4885) sur la biogenese des corticostéroides chez le rat. Bull. Soc. Chim. biol. (Paris)42, 913 (1960).Google Scholar
  312. Ronzoni, E.: Sodium pentobarbital anesthesia and the response of the adrenal cortex to stress. Amer. J. Physiol.160, 499 (1950).PubMedGoogle Scholar
  313. Rosenfeld, G.: Metabolic studies of intact perfused calf adrenals using tetrazolium. Arch. Biochem.62, 125 (1956).PubMedGoogle Scholar
  314. —, andW. D. Bascom: The inhibition of steroidogenesis by amphenone B: Studiesin vitro with the perfused calf adrenal. J. biol. Chem.222, 565 (1956).PubMedGoogle Scholar
  315. Rosenthal, N. R., andJ. W. Mason: Alterations in urinary 17α-hydroxycorticosteroid excretion associated with administration of reserpine in the Rhesus monkey. Psychopharmacologia (Berl.)2, 55 (1961).Google Scholar
  316. Roy, S., andV. B. Mahesh: Changes in steroid content of the adrenal of rats following prolonged administration of testosterone propionate with or without ACTH. Endocrinology74, 187 (1964).PubMedGoogle Scholar
  317. Royce, P. C., andG. Sayers: Blood ACTH: Effects of ether, pentobarbital, epinephrine, and pain. Endocrinology63, 794 (1958).PubMedGoogle Scholar
  318. Rubin, M. I., andP. L. Calcagno: Acute renal failure. Pathogenesis and management. Pediat. Clin. N. Amer.9, 155 (1962).PubMedGoogle Scholar
  319. Rudd, B. T., P. Sampson, andB. N. Brooke: A new fluorimetric method of plasma cortisol assay with a study of pituitary-adrenal function using metyrapone (SU 4885). J. Endocr.27, 317 (1963).PubMedGoogle Scholar
  320. Saffran, M., A. V. Schally, andB. G. Benfey: Stimulation of the release of corticotropin from the adenohypophysis by a neurohypophysial factor. Endocrinology57, 439 (1955).PubMedGoogle Scholar
  321. Salassa, R. M., andV. R. Mattox: Effects of a chemical inhibitor of 11β-hydroxylation on the urinary steroid pattern in primary hyperaldosteronism. J. Lab. clin. Med.54, 940 (1959).Google Scholar
  322. Sapeika, N.: The effect of chlorpromazine, iproniazide, and chloroquine on the adrenal ascorbic acid in the rat. Arch. int. Pharmacodyn.122, 196 (1959).PubMedGoogle Scholar
  323. Saroff, J., W. R. Slaunwhite jr.,G. Costa, andA. A. Sandberg: Steroid metabolites from cholesterol-C14 in a patient with adrenal cancer: Effects of Metopirone. J. clin. Endocr.23, 629 (1963).PubMedGoogle Scholar
  324. Saunders, J. C., N. J. Kothari, andI. Lourie: Phrenotropic drugs and neuroendocrine relations in man. Proc. West. Pharmacol. Soc.4, 59 (1961).PubMedGoogle Scholar
  325. Sayers, G.: The adrenal cortex and homeostasis. Physiol. Rev.30, 244 (1950).Google Scholar
  326. —, andM. A. Sayers: The pituitary-adrenal system. Recent Progr. Hormone Res.2, 81 (1948).PubMedGoogle Scholar
  327. Scavo, D., A. Jacobelli, C. Montervino, P. Cugini etM. Motolese: Etude de la reserve corticotrophique à l’aide de Metopiron chez les sujets atteints de cirrhose hépatique. Ann Endocr. (Paris)24, 1058 (1963).Google Scholar
  328. Schally, A. V., C. Y. Bowers, andW. Locke: Neurohumoral functions of the hypothalamus. Amer. J. med. Sci.248, 79 (1964).PubMedGoogle Scholar
  329. Schapiro, S., J. Marmorston andH. Sobel: The steroid feedback mechanism. Amer. J. Physiol.192, 58 (1958).PubMedGoogle Scholar
  330. Schlatmann, R. J. A. F. M., A. P. Jansen, H. Prenen, J. K. van der Korst, andC. L. H. Majoor: The natriuretic and aldosterone-suppressive action of heparin and some related polysulfated polysaccharides. J. clin. Endocr.24, 35 (1964).PubMedGoogle Scholar
  331. Schneider, P. B.: Falsely abnormal responses of normal subjects to the Metopirone (Su-4885) test for pituitary ACTH reserve. J. clin. Endocr.24, 218 (1964).PubMedGoogle Scholar
  332. Schotté, O. E., andW. B. Christiansen: Influence of amphenone B — a cortical inhibitor — upon regeneration in normal and in hypophysectomized newts. Anat. Rec.128, 619 (1957).Google Scholar
  333. Schricker, J. A., G. R. Fisher, W. W. Tullner, andR. Hertz: The effect of amphenone-B on the cholesterol and ascorbic acid content of the rat adrenal. Endocrinology51, 394 (1952).PubMedGoogle Scholar
  334. Schuler, W., u.R. Meier: Wirkung von Thiosemicarbazonen auf die Drüsen mit innerer Sekretion. Arch. int. Pharmacodyn.87, 290 (1951).PubMedGoogle Scholar
  335. Seller, R. H., C. D. Swartz, O. Ramirez-Muxo, A. H. Brest, andJ. H. Moyer: Aldosterone antagonists in diuretic therapy. Arch. intern. Med.113, 350 (1964).PubMedGoogle Scholar
  336. Sevy, R. W., E. A. Ohler, andA., Weiner: Effect of chlorpromazine on stress induced adrenal ascorbic acid depletion. Endocrinology61, 45 (1957).PubMedGoogle Scholar
  337. Shaldon, S., andJ. R. McLaren: An 11β-hydroxylase inhibitor in the treatment of resistant ascites. Lancet1960II, 1330.Google Scholar
  338. Shaldon, S., J. R. Mclaren andS. Sherlock: Resistant ascites treated by combined diuretic therapy. (Spironolactone, mannitol, and chlorothiazide.) Lancet1960I, 609.Google Scholar
  339. Sharp, G. W. G., andA. Leaf: Biological action of aldosteronein vitro. Nature (Lond.)202, 1185 (1964a).Google Scholar
  340. Sharp, G. W. G., andA. Leaf: Studies on the mechanism of mineralocorticoid activity. Program, 46th Meeting, The Endocrine Society, 1964b, p. 64, Abstr. 83.Google Scholar
  341. Sheehan, H. L., V. K. Summers, andJ. Nichols: DDD therapy in Cushing’s syndrome. Lancet1953I, 312.Google Scholar
  342. Sholiton, L. J. E. E. Werk jr., andJ. MacGee: The extra-adrenal metabolism of cortisol in triparanol treated subjects. Metabolism11, 1265 (1962).Google Scholar
  343. Shuster, S.: The control of corticotrophin secretion in man. Proc. roy. Soc. Med.55, 131 (1962).PubMedGoogle Scholar
  344. —, andM. Chadwick: Modification of the tuberculin reaction by histamine and pyrogen. J. invest. Derm.41, 53 (1963).PubMedGoogle Scholar
  345. Simkin, B., andR. Arce: Response of obese patients to an 11β-hydroxylase inhibitor, methopyrapone (SU-4885). Proc. Soc. exp. Biol. (N.Y.)111, 780 (1962).Google Scholar
  346. Singer, B.: Effect of aldosterone-antagonist, SC 8109, on the secretion of aldosterone in normal rats. Endocrinology65, 512 (1959).PubMedGoogle Scholar
  347. Slater, J. D. H., A. Moxham, R. Hurter, andJ. D. N. Nabarro: Clinical and metabolic effects of aldosterone antagonism. Lancet1959II, 931.Google Scholar
  348. Slusher, M. A., andB. Browning: Morphine inhibition of plasma corticosteroid levels in chronic venous-catheterized rats. Amer. J. Physiol.200, 1032 (1961).Google Scholar
  349. —, andJ. E. Hyde: Inhibition of adrenal corticosteroid release by brain stem stimulation in cats. Endocrinology68, 773 (1961).Google Scholar
  350. Smelik, P. G., andC. H. Sawyer: Pharmacological control of adrenocortical and gonad secretions. In: Annual Review of Pharmacology, vol. 2, p. 313, ed.W. C. Cutting, R. H. Dreisbach, H. W. Elliott. Palo Alto, Cal.: Annual Reviews, Inc., 1962a.Google Scholar
  351. ——: Effects of implantation of cortisol into the brain stem or pituitary gland on the adrenal response to stress in the rabbit. Acta endocr. (Kbh.)41, 561 (1962b).Google Scholar
  352. Smith, L. L., andD. M. Teller: Synthesis of some pregnane 16-thioesters. J. med. Chem.7, 531 (1964).PubMedGoogle Scholar
  353. Smith, R. L., R. P. Maickel, andB. B. Brodie: ACTH-hypersecretion induced by phenothiazine tranquilizers. J. Pharmacol. exp. Ther.139, 185 (1963).PubMedGoogle Scholar
  354. Smith, W. G.: Spironolactone and gynaecomastia. Lancet1962II, 886.Google Scholar
  355. Sobel, E. H., A. E. Renold, J. E. Bethune, J. J. Hoet, W. J. Reddy, andG. W. Thorn: Effects of hypophysectomy and of amphenone administration in a child with functioning metastatic, adrenal carcinoma. Amer. J. Med.24, 482 (1958).PubMedGoogle Scholar
  356. Sobel, H., S. Schapiro, andJ. Marmorston: Influence of morphine on urinary corticoid excretion by guinea pigs following exposure to cold and administration of Pitressin. Amer. J. Physiol.195, 147 (1958).PubMedGoogle Scholar
  357. Southren, A. L., L. Strom, H. Ross, andA. Ratuschni: Effects of o.p’ DDD on cortisol metabolism in adrenal carcinoma. Program, 46th Meeting, The Endocrine Society, 1964, p. 152, Abstr. 260.Google Scholar
  358. —,S. Weisenfeld, A. Laufer, andM. G. Goldner: Effect of o,p’ DDD in a patient with Cushing’s syndrome. J. clin. Endocr.21, 201 (1961).Google Scholar
  359. Sprunt, J. G., A. C. Brownie, andJ. S. Kinnear: Detection of incomplete ablation after yttrium-90 implantation of pituitary. Brit. med.J. 1963 II, 1375.Google Scholar
  360. Sprunt, J. G., R. Rutherford, J. H. Mestman, andD. H. Nelson: Mechanism of the inhibitory effect of ethinyl estradiol on adrenal cortical response to methopyrapone. Program, 46th Meeting, The Endocrine Society, 1964, p. 154, Abstr. 263.Google Scholar
  361. Steiker, D. D., A. M. Bongiovanni, W. R. Eberlein, andG. Leboeuf: Adrenocortical and adrenocorticotropic function in children. J. Pediat.50, 884 (1961a).Google Scholar
  362. ————: Pituitary-adrenocortical reserve in children. Amer. J. Dis. Child.102, 575 (1961b).Google Scholar
  363. Steinberg, D., andD. S. Fredrickson: Inhibitors of cholesterol biosynthesis and the problem of hypercholesterolemia. Ann. N.Y. Acad. Sci.64, 579 (1956).PubMedGoogle Scholar
  364. Stoner, H. B.: Effect of 2,2-bis-(parachlorophenyl)-1,1-dichloroethane (DDD) on the adrenal cortex of the rat. Nature (Lond.)172, 1044 (1953).Google Scholar
  365. Suzuki, T., K. Yamashita, M. Kamo, andK. Hirai: Effect of sodium pentobarbital and sodium hexobarbital anesthesia on the adrenal 17-hydroxycorticosteroid secretion rate in the dog. Endocrinology70, 71 (1962).PubMedGoogle Scholar
  366. Swingle, W. W., P. Seay, J. Perlmutt, E. J. Collins, G. Barlow jr., andE. J. Fedor: An experimental study of pseudopregnancy in rat. Amer. J. Physiol.167, 586 (1951).PubMedGoogle Scholar
  367. Talbott, J. H., W. F. Lever, andW. V. Consolazio: Metabolic studies on patients with pemphigus. J. invest. Derm.3, 31 (1940).Google Scholar
  368. Taliaferro, I., andL. Leone: Inhibitory effect of Perthane (2,2-bis-[para-ethylphenyl]-1,1-dichloroethane) on adrenocortical function in human subjects. New Engl. J. Med.257, 855 (1957).PubMedGoogle Scholar
  369. Talwalker, P. K., J. Meites, C. S. Nicoll, andT. F. Hopkins: Effects of chlorpromazine on mammary glands of rats. Amer. J. Physiol.199, 1073 (1960).PubMedGoogle Scholar
  370. Tanabe, T., andE. J. Cafruny: Adrenal hypertrophy in rats treated chronically with morphine. J. Pharmacol. exp. Ther.122, 148 (1958).PubMedGoogle Scholar
  371. Taylor, J. A. T.: Modification of adrenocortical hyperfunction by an imidazole derivative. J. Amer. med. Ass.181, 766 (1962).Google Scholar
  372. Thorn, G. W., A. E. Renold, A. Goldfien, D. H. Nelson, W. J. Reddy andR. Hertz: Inhibition of corticosteroid secretion by amphenone in a patient with adrenocortical carcinoma. New Engl. J. Med.254, 547 (1956).PubMedGoogle Scholar
  373. Tixier-Vidal, A., etI. Assenmacher: Action de la métopirone sur la préhypophyse du Canard mâle: essai d’identification des cellules corticotropes. C.R. Soc. Biol. (Paris)157, 1350, (1963).Google Scholar
  374. Törnblom, N.: Administration of DDD (2,2-bis-[parachlorophenyl]-1,1-dichloroethane) to diabetics with hyaline vascular changes and hyperpolysaccharidemia. A preliminary report. Acta med. scand.154, 83 (1956).PubMedGoogle Scholar
  375. Tomlinson, C. C.: Juvenile pemphigus. Effects of germanin in 3 cases. Arch. Derm. Syph. (Chic.)38, 555 (1938).Google Scholar
  376. Tomkins, G. M., H. Sheppard, andI. L. Chaikoff: Cholesterol synthesis by liver. IV. Suppression by steroid administration. J. biol. Chem.203, 781 (1953).PubMedGoogle Scholar
  377. Treadwell, B. L. J., O. Savage, E. D. Sever, andW. S. C. Copeman: Pituitaryadrenal function during corticosteroid therapy. Lancet1963I, 355.Google Scholar
  378. Troop, R. C.: Influence of gonadal hormones on the metabolism of cortisone. Endocrinology64, 671 (1959).PubMedGoogle Scholar
  379. Tullner, W. W.: Mediation of progestational action of amphenone by the rabbit adrenal. Proc. Soc. exp. Biol. (N.Y.)98, 157 (1958).Google Scholar
  380. —: Endocrine effects of methylenedianiline in the rat, rabbit and dog. Endocrinology66, 470 (1960).Google Scholar
  381. —,M. M. Graff, andR. Hertz: Amphenone inhibition of adrenal corticosteroid output in the hypophysectomized dog. Endocrinology58, 802 (1956).PubMedGoogle Scholar
  382. —, andR. Hertz: Effect of intravenous o,p’ DDD on plasma 17-hydroxycorticoid secretion in the dog. Endocrinology66, 494 (1960).Google Scholar
  383. ——: Suppression of corticosteroid production in the dog by Monase. Proc. Soc. exp. Biol. (N.Y.)116, 837 (1964).Google Scholar
  384. Verne, J., M. Marois, S. Hébert etG. Marois: Su 4885, gestation et cortex surrénal chez la ratte. C.R. Soc. Biol. (Paris)154, 1359 (1960).Google Scholar
  385. Verne, J., etR. Wegmann: Inhibition spécifique de la surrénale. Comm. 73e Congr. Ass. Franç. avance. Sci., Poitiers 1954, p. 438.Google Scholar
  386. Veyrat, R., E. Engel, P. Ducommun etA.-F. Muller: Utilité de l’association des salurétiques et des inhibiteurs de l’aldostérone (SC 9420 et SU 4885) dans le traitement des oedèmes réfractaires. Helv. med. Acta27, 683 (1960).PubMedGoogle Scholar
  387. —,J. Fabre etA.-F. Muller: Inhibition sélective de la sécrétion de l’aldostérone par un héparinoïde semi-synthétique (Ro 18307). Helv. med. Acta29, 543 (1962).PubMedGoogle Scholar
  388. Vies, J. van der: Corticoid productionin vitro as a test of adrenocortical function in rats. Acta endocr. (Kbh.)33, 59 (1960).Google Scholar
  389. Vilar, O., andW. W. Tullner: Effects of o,p’ DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology65, 80 (1959).PubMedGoogle Scholar
  390. Vogt, M.: The effects of hexoestrol and of “amphenone B” on morphology and function of the rat adrenal cortex. Yale J. Biol. Med.29, 469 (1957).PubMedGoogle Scholar
  391. Wallace, E. Z., J. N. Silverstein, L. S. Villadolid andS. Weisenfeld: Cushing’s syndrome due to adrenocortical hyperplasia. New Engl. J. Med.265, 1088 (1961).PubMedGoogle Scholar
  392. Waxman, S. H., andV. C. Kelley: Metopirone test in congenital adrenal hyperplasia. Amer. J. Dis. Child.102, 576 (1961).Google Scholar
  393. Weber, A. F., J. T. Bell jr., andA. F. Sellers: Studies of the bovine adrenal gland. II. The histological and cytochemical effects of the administration of 1,1-dichloro-2,2-bis-(p-chlorophenyl) ethane on the adrenal cortices of dairy calves. Amer. J. vet. Res.19, 51 (1958).PubMedGoogle Scholar
  394. Weis, M., andR. Gaunt: The effect of germanin on the adrenal cortex. Anat. Rec.96, 80 (1946).Google Scholar
  395. Wells, H., F. N. Briggs, andP. L. Munson: The inhibitory effect of reserpine on ACTH secretion in response to stressful stimuli. Endocrinology59, 571 (1956).PubMedGoogle Scholar
  396. —,E. A. Milgram, andP. L. Munson: The effect of diphenylhydantoin on the secretion of ACTH in rats. Fed. Proc.18, 458 (1959).Google Scholar
  397. Wells, H. G., E. M. Humphreys, andE. G. Work: Significance of the increased frequency of selective cortical necrosis of adrenal as a cause of Addison’s disease. J. Amer. med. Ass.109, 490 (1937).Google Scholar
  398. Werk jr.,E. E., J. MacGee, andL. J. Sholiton: Effect of diphenylhydantoin on cortisol metabolism in man. J. clin. Invest.43, 1824 (1964).PubMedGoogle Scholar
  399. West, C. D., L. F. Kumagai, E. L. Simons, O. V. Dominguez, andD. L. Berliner: Adrenocortical carcinoma with feminization and hypertension associated with a defect in 11β-hydroxylation. J. clin. Endocr.24, 567 (1964).PubMedGoogle Scholar
  400. Westermann, E. O., R. P. Maickel, andB. B. Brodie: On the mechanism of pituitaryadrenal stimulation by reserpine. J. Pharmacol. exp. Ther.138, 208 (1962).PubMedGoogle Scholar
  401. Wexler, B. C.: Reproductive defects and abnormal progeny of rats treated with triparanol: prevention of abnormalities by ACTH. Endocrinology74, 64 (1964).PubMedGoogle Scholar
  402. Wied, D. de: The site of the blocking action of dexamethasone, on stress-induced pituitary ACTH release. J. Endocr.29, 29 (1964).Google Scholar
  403. Wiggins, R. A., M. E. Hutchin, J. V. Carbone, andP. D. Doolan: Effect of spirolactone SC 8109 on renal function in normal human subjects. Proc. Soc. exp. Biol. (N.Y.)100, 625 (1959).Google Scholar
  404. Williamson, H. E.: Mechanism of the antinatriuretic action of aldosterone. Biochem. Pharmacol.12, 1449 (1963).PubMedGoogle Scholar
  405. —, andF. E. Shideman: Inhibition of glycogenic, myotrophic and androgenic activity of certain steroids by 2-amino-4-(p-chloroanilino)-s-triazine in the rat. Fed. Proc.16, 347 (1957).Google Scholar
  406. —— andD. A. LeSher: Antagonism of the effects of certain steroids on the renal excretion of water and electrolytes by 2-amino-4-(p-chloroanilino)-5-triazine. J. Pharmacol. exp. Ther.126, 82 (1959).PubMedGoogle Scholar
  407. Wilson, D., andF. C. Goetz: Selective hypoaldosteronism after prolonged heparin administration. Amer. J. Med.36, 635 (1964).PubMedGoogle Scholar
  408. Wong, T.-W., andN. E. Warner: Inhibition of dimethylbenzanthracene-induced adrenal cortical necrosis. Endocrinology74, 284 (1964).PubMedGoogle Scholar
  409. Woodbury, D. M.: Effects of chronic administration of anticonvulsant drugs, alone and on combination with desoxycorticosterone, on electroshock seizure threshold and tissue electrolytes. J. Pharmacol. exp. Ther.105, 46 (1952).PubMedGoogle Scholar
  410. —: Effect of hormones on brain excitability and electrolytes. Recent Progr. Hormone Res.10, 65 (1954).Google Scholar
  411. Yates, F. E., andJ. Urquhart: Control of plasma concentrations of adrenocortical hormones. Physiol. Rev.42, 359 (1962).PubMedGoogle Scholar
  412. Zarrow, M. X., L. M. Horger, andJ. L. McCarthy: Atrophy of adrenal gland following thiouracil and Vit. B12. Proc. Soc. exp. Biol. (N.Y.)94, 348 (1957).Google Scholar
  413. Zimmermann, B., H. S. Bloch, W. L. Williams, C. R. Hitchcock, andB. Hoelscher: The effects of DDD [1,1-dichloro-2,2-bis-(p-chlorophenyl)-ethane] on the human adrenal. Attempts to use an adrenal-destructive agent in the treatment of, disseminated mammary and prostatic cancer. Cancer9, 940 (1956).PubMedGoogle Scholar
  414. Zizine, L.: Study of the pituitary corticotropin content in rats given testosterone. C.R. Soc. Biol. (Paris)147, 1223 (1953).Google Scholar

Copyright information

© Springer-Verlag 1965

Authors and Affiliations

  • Robert Gaunt
    • 1
  • J. J. Chart
    • 1
  • A. A. Renzi
    • 1
  1. 1.Research DepartmentCIBA Pharmaceutical CompanySummit

Personalised recommendations